XML 42 R30.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Equity (Tables)
3 Months Ended
Mar. 31, 2021
Schedule of allocation of total stock-based compensation expense

Three Months Ended

March 31, 

(In thousands)

    

2021

    

2020

Cost of revenue

$

111

$

82

Sales and marketing expenses

978

1,246

Research and development expenses

97

88

Reimbursement, general and administrative expenses

1,271

1,312

Total stock-based compensation expense

$

2,457

$

2,728

Schedule of stock option activity

    

Weighted-

Weighted-

Average

Average

Aggregate

Options

Exercise Price

Remaining

Intrinsic

(In thousands except options and per share data)

Outstanding

Per Share (1)

Contractual Life

Value (2)

Balance at December 31, 2020

1,039,709

$

36.43

5.6 years

$

13,381

Granted

132,606

$

51.60

Exercised

(53,967)

$

24.00

$

1,516

Forfeited

(10,866)

$

46.28

Cancelled/Expired

(5,982)

$

46.18

Balance at March 31, 2021

1,101,500

$

38.72

5.6 years

$

18,893

Options exercisable at March 31, 2021

546,067

$

30.27

4.7 years

$

14,229

(1)The exercise price of each option granted during the period shown was equal to the market price of the underlying stock on the date of grant.
(2)The aggregate intrinsic value of options exercised represents the difference between the exercise price of the option and the closing stock price of our common stock on the date of exercise. The aggregate intrinsic value of options outstanding represents the difference between the exercise price of the option and the closing stock price of our common stock on the last trading day of the period.
Time-Based Restricted Stock Units  
Schedule of stock-settled restricted stock unit activity

Weighted-

    

    

Average Grant

    

Aggregate

Units

Date Fair Value

Intrinsic

(In thousands except unit and per unit data)

Outstanding

Per Unit

Value (1)

Balance at December 31, 2020

211,469

$

48.29

$

9,503

Granted

48,893

$

51.60

Vested

(61,682)

$

49.49

Cancelled

(3,382)

$

54.25

Balance at March 31, 2021

195,298

$

48.63

$

10,642

Deferred and unissued at March 31, 2021(2)

6,469

$

38.94

$

352

(1)The aggregate intrinsic value of restricted stock units outstanding was based on our closing stock price on the last trading day of the period.
(2)For the three months ended March 31, 2021, there were no restricted stock units granted to non-employee directors in lieu of their quarterly cash retainer payments. As of March 31, 2021, there were 6,469 outstanding restricted stock units that had been previously granted to non-employee directors in lieu of their quarterly cash retainer payments.
Performance-based stock-settled restricted stock units  
Schedule of stock-settled restricted stock unit activity

Performance-

Weighted-

    

Based

    

Average Grant

    

Aggregate

Units

Date Fair Value

Intrinsic

(In thousands except unit and per unit data)

Outstanding

Per Unit

Value (1)

Balance at December 31, 2020

79,303

$

47.83

$

3,564

Granted

35,929

$

51.60

Vested

(34,159)

$

33.98

Cancelled

(19,032)

$

69.17

Balance at March 31, 2021

62,041

$

51.10

$

3,381

(1)The aggregate intrinsic value of performance-based restricted stock units outstanding was based on our closing stock price on the last trading day of the period.